Skip to main content

“After two exceptionally dynamic years, we delivered another year of strong results. Despite the challenging operating environment, our growth was broad-based across the portfolio and the geographies, and we see us a good year ahead of our mid-term plan. Not surprisingly, 2023 will show a trend back towards our underlying growth path.

As we look ahead, we find the fundamental growth drivers in our markets fully intact. Demand for biopharmaceuticals is on the rise in all indication areas and regions, and at the same time the biotech industry is in an extraordinarily innovative phase. We are excellently positioned to support our customers in their endeavors and to seize the opportunities that arise from this. Substantial investments into capacities and acquisitions that expand our capabilities will therefore remain part of our growth strategy.”

Chairman’s Message

Sales revenue


in constant FX: +15.1%

Underlying EBITDA



Order intake


in constant FX: -13.0%




Market capitalization



Group Business Development

Following extraordinary growth in 2020 and 2021, Sartorius Stedim Biotech, a leading partner of the biopharma industry, again outperformed the market in fiscal 2022. According to preliminary figures, the company recorded double-digit percentage growth in sales revenue and earnings year-over-year.

Group Business Development


Following the exceptionally strong previous years, Sartorius Stedim Biotech expects further growth in 2023 despite demand normalization and anticipated further declines in the Covid-19-related business. In addition, management adjusted the medium-term sales revenue forecast in light of increased inflation and associated price adjustments.



Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the mid to high single-digit percentage range. Acquisitions are anticipated to contribute around 1 percentage point to growth. The Group’s underlying EBITDA margin should be around the level of the prior year (35.0 percent).



Strategy and Long-Term Targets

Sartorius Stedim Biotech now expects sales revenue of around 4.4 billion euros in 2025 (previously around 4 billion euros). The forecast for the Group’s underlying EBITDA margin in 2025 remains unchanged at more than 35 percent.